Indian regulators have turned their attention to pay-for-delay agreements, making the nation the latest to scrutinize such agreements that have particular impact on the pharmaceutical industry.
According to reports, the Competition Commission of India is examining patent settlements made between foreign brand-name pharmaceutical companies and their generic counterparts in India. Reports say the probe is in response to concerns that some of those settlements may lead to cheaper, generic drugs being unavailable to consumers.
Reports say at least two patent settlements are being investigated by the CCI. One of which involves Roche’s lung cancer drug and an agreement the pharma giant made with generic drug maker Cipla. The other, reports say, involves Glenmark Pharmaceuticals, one of India’s largest generic companies, and an agreement with Merck over a diabetes drug.
Officials noted that the agreements will be probed on a case-by-case basis to determine if they resulted in anticompetitive effects.
Full content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI